Targeted exosome therapy in 2026: overview
Targeted exosome therapy uses exosomes or related extracellular vesicles to carry therapeutic molecules toward selected cells or tissues. Their biological membranes and ability to transport proteins and nucleic acids make them attractive delivery vehicles, while surface engineering and producer-cell design can influence where they go. The field is moving from proof-of-concept targeting toward more controlled delivery, but consistent cargo loading, vesicle production, tissue access and off-target effects remain important technical hurdles.
Recent work is testing both biological and engineered routes. In August 2026, University of Sichuan researchers reported dual-engineered small extracellular vesicles carrying miR-126 for age-related bone loss; researchers from University of Science and Technology of China, Peking University and Wuhan University described microfluidic synthesis of biomimetic vesicle-inspired liposomes. A September 2026 study examined surface-engineered vesicle stability during pulmonary delivery across airway mucus and tissue barriers. In July 2026, news reported CytoNiche’s IND clearance for STX11101 Injection, adding a clinical-development signal to research on organ-specific delivery.
takeaways:[]
funding_note:[]
approach_texts:[]
faq:[]
- 1Engineering the address: Genetically engineered producer cells and post-isolation surface modification offer ways to improve targeting, but each adds process and product-control demands.
- 2Cargo is expanding: Recent work on miR-126 delivery and vesicle-inspired liposomes points to growing interest in nucleic-acid payloads and engineered alternatives to natural vesicles.
- 3Translation remains difficult: Low production, heterogeneous vesicles and barriers to tissue access keep scalable manufacturing and reliable biodistribution central challenges.
Top organizations working on targeted exosome therapy
Ranked by Linknovate activity score · last 24 monthsThe activity score adds up the relevance of every patent, publication, grant and news item linking an organization to targeted exosome therapy. Showing 7 of 3,000 organizations.
| # | Organization | Approach | Signals (24 mo) | Momentum | Why it matters |
|---|---|---|---|---|---|
| 1 | 
Huazhong University of Science and Technology
Research · China |
Post-isolation surface modification | PUB 173 · NEWS 18 | +42% | Recently, researchers developed transferrin-mediated targeting of ginger-derived extracellular vesicles for oral colorectal cancer therapy. |
| 2 | 
Sun Yat Sen University
Research · China |
Post-isolation surface modification | PUB 188 | +47% | Its researchers have surface-engineered umbilical-cord mesenchymal-stem-cell vesicles for targeted osteoarthritis therapy, including cartilage-regeneration applications. |
| 3 | 
University of Sichuan
Research · China |
Genetically engineered producer cells | PUB 170 · NEWS 9 | +27% | Recently, researchers reported dual-engineered small extracellular vesicles for targeted miR-126 delivery to reduce age-related bone loss. |
| 4 | SJ
Shanghai Jiao Tong University School Of Medicine
Research |
Genetically engineered producer cells | PUB 170 · NEWS 7 | +81% | Researchers have developed CAR-T-cell-derived vesicles targeting FAP for intrauterine adhesions and surface-engineered, GE11-functionalized exosomes for targeted glioma drug delivery. |
| 5 | 
Fudan University
Research · China |
Post-isolation surface modification | PUB 161 · NEWS 3 | +39% | Researchers developed a microfluidic platform for multifunctional small extracellular-vesicle surface modification and have explored ultrasound-programmable tumor-vesicle delivery for cancer therapy. |
| 6 | 
Southern Medical University
Research · China |
Native cell-derived vesicles | PUB 164 · NEWS 2 | +27% | Researchers have investigated integrin β4-enriched small extracellular vesicles as carriers targeting hepatocellular-carcinoma lung metastases. |
| 7 | 
Nanjing Medical University
Research · China |
Genetically engineered producer cells | PUB 125 · NEWS 4 | +19% | Recently, researchers reported a gene-circuit approach for assembling siRNA in endogenous small extracellular vesicles to suppress KRAS in colorectal cancer. |
| 8 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
| 9 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
| 10 | ··Hidden organizationCompany | Approach | PAT 00 · PUB 00 GRANTS 0 · NEWS 00 | +00% | Available to registered users. |
Startups to watch and leading research centers
Startups to watch 18 total
Evox TherapeuticsUnited KingdomEvox develops exosome therapeutics for serious diseases; its work includes therapeutic-polypeptide delivery and antibody-displaying extracellular vesicles for targeted cancer therapy.
Exostemtech Co.South KoreaThe company describes its focus as developing therapeutic agents based on stem-cell-derived exosomes.
Diadem BiotherapeuticsUnited StatesIts patent portfolio includes engineered extracellular vesicles designed as agonists and artificial synapses, providing a platform for therapeutic vesicle applications.- ··Hidden startupCountryAvailable to registered users, with funding and founding year.
- ··Hidden startupCountryAvailable to registered users, with funding and founding year.
Leading research institutions 2,742 total
- Huazhong University of Science and TechnologyChinaRecently, researchers developed transferrin-mediated targeting of ginger-derived extracellular vesicles for oral colorectal cancer therapy.
- Sun Yat Sen UniversityChinaIts researchers have surface-engineered umbilical-cord mesenchymal-stem-cell vesicles for targeted osteoarthritis therapy, including cartilage-regeneration applications.
- University of SichuanChinaRecently, researchers reported dual-engineered small extracellular vesicles for targeted miR-126 delivery to reduce age-related bone loss.
- ··Hidden research institutionCountryAvailable to registered users, with their key researchers.
- ··Hidden research institutionCountryAvailable to registered users, with their key researchers.
Where targeted exosome therapy innovation happens
Share of documents with at least one organization from each country.
Open the interactive map with all 3,000 organizationsMain technical approaches
Last 24 months| Approach | What it is | Documents | Leading organizations |
|---|---|---|---|
| Native cell-derived vesicles | Vesicles are collected from naturally producing cells, preserving biological features but leaving source variability and limited yield as trade-offs. | 2,335 |
World Stem Cells, Llc, U.S. Food and Drug Administration, AIM Co. |
| Genetically engineered producer cells | Producer cells are modified to package cargo or display targeting features, enabling integrated design but adding cell-line and manufacturing complexity. | 230 |
Hanyang University, Nanjing Medical University, University of Tabuk |
| Post-isolation surface modification | Isolated vesicles are functionalized to improve tissue recognition, offering flexible targeting but risking changes to stability or cellular uptake. | 328 |
Chandigarh University, Soochow University, Taipei Medical University |
| Exogenous cargo loading | Therapeutic molecules are loaded into isolated vesicles, allowing payload choice but making loading efficiency and vesicle integrity key constraints. | 567 |
Jilin University, Islamic Azad University, Shandong Second Medical University (Fuyanshan Campus) |
| Hybrid and mimetic vesicles | Vesicles are combined with synthetic or other biological materials to tune delivery, trading natural functions for greater design and production complexity. | 143 |
Shanghai JiaoTong University, University of Sichuan, Shenyang Pharmaceutical University |
Emerging trends
Last 12 months vs previous 36 monthsTerms whose frequency in the last 12 months grew the most compared with the previous 36 months.
Funding and investment
Recent funding rounds
FACTS records $77.1 million in grants across 65 grants since 2020, alongside 10 funding rounds totaling about $1.29 billion. The round-level entries include broad institutional funding, so treat that aggregate as a noisy signal rather than therapy-specific investment.
Patent landscape
Top patent holders · last 24 monthsRecent developments
Latest news, duplicates removed- Aug 2026Newswise — COLUMBUS, Ohio – Red blood cells serve as the foundation for nanocarriers that show promise in a new study as effective and efficient vehicles for gene therapy, tumor targeting and other medical treatments.…Newswise Feature Channel: Regenerative Medicine
- Aug 2026Abstract Traumatic brain injury (TBI) remains a major unmet clinical challenge owing to its complex pathophysiology, profound heterogeneity, and limited regenerative capacity of the adult central nervous system (CNS).…Frontiers in Neuroscience | New and Recent Articles
- Jun 2026TORONTO, Ontario and HAIFA, Israel, June 01, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based…GlobeNewswire - News from Canada
- May 2026SHIRLEY, NY, May 28, 2026 /24-7PressRelease/ -- By integrating high-fidelity physiological modeling, system-specific vesicle trafficking, advanced in vivo imaging, and quantitative pathology validation, the company…Press Release and Top News From 24-7 Press Release Newswire
- Month 20XXHidden developmentAvailable to registered users with alerts enabled.
Frequently asked questions about targeted exosome therapy
What companies are working on targeted exosome therapy?
Evox Therapeutics, Exostemtech Co. and Diadem Biotherapeutics are named startups in the field; FACTS lists 258 companies overall. Evox works on therapeutic-polypeptide delivery and antibody-displaying vesicles for targeted cancer therapy. The other startup profiles describe stem-cell-derived exosome therapeutics and engineered extracellular vesicle platforms, respectively.
Which universities and research centers lead targeted exosome therapy research?
Huazhong University of Science and Technology, Sun Yat Sen University and University of Sichuan are among the leading research organizations listed. Their work includes transferrin-targeted ginger-derived vesicles, surface-engineered vesicles for osteoarthritis and dual-engineered vesicles carrying miR-126. Shanghai Jiao Tong University School Of Medicine and Fudan University also appear among the active research organizations.
How much funding has targeted exosome therapy received?
FACTS records $77,100,085 in grants across 65 grants since 2020, plus 10 reported funding rounds totaling $1,290,452,398. These are different funding categories, and the round entries include broad institutional grants and other activity. The round aggregate should therefore be treated cautiously rather than as a clean measure of capital invested specifically in targeted exosome therapy.
Who holds the most targeted exosome therapy patents?
Mercury.Io is the largest named patent holder in FACTS, with 7 patents. ChinaMedical University has 5; Lonza Sales Ltd and Yoltech Therapeutics Co., Ltd each have 4. Cornell University, Evox Therapeutics, Dexon Pharmaceuticals Inc. and EXORNA BIOSCIENCE SHANGHAI Co. each have 3 listed patents.
Is targeted exosome therapy patent activity growing?
Patent activity is contracting in the year-over-year comparison: the 24-month window contains 181 patents, and patent growth is -57.5%. This contrasts with publication activity, which FACTS reports grew 46.4% in the last-year comparison. The divergence suggests research output is expanding while patent activity is moving in the opposite direction.
How mature is targeted exosome therapy?
The field remains research-heavy, with 118 clinical trials listed across the topic and 29 clinical-trial records in 2025. Research spans multiple delivery designs and therapeutic areas, while the available figures do not establish how many programs have reached approval. Production consistency, cargo loading, targeting performance and translation from experimental results remain important considerations.
What are the latest developments in targeted exosome therapy?
Recent developments include University of Sichuan’s dual-engineered vesicles for miR-126 delivery, reported in August 2026, and a September 2026 study of surface-engineered vesicles for pulmonary delivery. In July 2026, news reported CytoNiche’s IND clearance for STX11101 Injection. Other recent research examines colon-responsive delivery designs, brain gene delivery and microfluidic production of vesicle-inspired liposomes.
What are the main approaches in targeted exosome therapy and how do they differ?
FACTS identifies five approaches: native cell-derived vesicles, genetically engineered producer cells, post-isolation surface modification, exogenous cargo loading, and hybrid and mimetic vesicles. They differ in where engineering occurs: in the source cell, on isolated vesicles, in the cargo-loading step or through combining vesicles with other materials. More customization can improve delivery design but may add manufacturing and product-control challenges.
Which countries lead targeted exosome therapy?
China leads the country-level activity listed in FACTS, with 12,688 documents and a 47.8% share; the United States follows with 7,357 documents and a 27.7% share. India and the United Kingdom are also prominent, with 2,236 and 2,215 documents, respectively. These figures describe document activity, not clinical or commercial leadership.
What are the applications of targeted exosome therapy?
Cancer therapy is the largest listed application, with 2,930 documents; inflammatory and metabolic disease has 1,954, and neurological disorders has 1,788. Other areas include musculoskeletal repair and wound and skin repair. Recent research also explores bone loss, pulmonary delivery, brain gene delivery and colorectal cancer, showing the range of tissues and conditions under investigation.